UNSPSC 51162105: Ethambutol/isoniazid/rifampicin

Definition: This classification is for a combination medication for TB treatment. The first component, ETHAMBUTOL, has US FDA Unique Ingredient Identifier of 8G167061QZ. ETHAMBUTOL is an International Non-Proprietary Name or INN. The second component, ISONIAZID, has US FDA Unique Ingredient Identifier of V83O1VOZ8L. ISONIAZID is an International Non-Proprietary Name or INN. The third component, RIFAMPICIN, has US FDA Unique Ingredient Identifier of VJT6J7R4TR. RIFAMPICIN is an International Non-Proprietary Name or INN.

UNSPSC 51162105 Ethambutol/isoniazid/rifampicin is a Commodity code that encompasses pharmaceutical products used in tuberculosis treatment protocols, though recent state and local solicitations tagged with this code show minimal direct relevance to the specific drug formulation named. The available opportunities under this code do not reflect procurement of ethambutol/isoniazid/rifampicin combinations; instead, they capture a broader range of pharmaceutical and medical supply contracting activities including emergency medical services drug protocols, long-term care facility pharmacy services, forensic drug standards, opioid use disorder treatment funding, and naloxone distribution. The issuing bodies span county health departments, city fire departments, regional mental health centers, and county forensic laboratories across multiple states, reflecting fragmented procurement across different health-sector and public-safety jurisdictions rather than centralized pharmaceutical purchasing.

Recent solicitations appear geographically dispersed, with activity concentrated in Florida (Collier County, Seminole County, Pinellas County), Wisconsin (Dane County), Oregon (Washington County), Arizona (Tucson), Texas (West Texas Centers, Bernalillo County New Mexico), and the District of Columbia. The most substantive recent opportunity is Dane County's RFP 2026RFP061PR for comprehensive pharmaceutical services to Badger Prairie Health Care Center, a long-term care facility, with proposals due October 22, 2026, structured as a five-year contract with local-vendor preference (5 bonus points for Dane County location, 2 for adjacent counties) and annual funding of approximately $125,000. The City of Tucson Fire Department's RFP 260217 for BLS/ALS pharmaceuticals and vending-machine services (proposals due June 24, 2026, federally funded through ARPA, HUD, and FTA) and West Texas Centers' RFP RX1001 for prescription pharmacy services across 35 sites in 23 counties (proposals due August 21, 2026) represent additional opportunities, though neither directly targets the specific ethambutol/isoniazid/rifampicin formulation. The code shows minimal recent activity directly tied to tuberculosis pharmaceutical procurement.